Nucleoside analogues and HIV: the combined cost to mitochondria

Abstract
Highly active antiretroviral therapy (HAART) has revolutionized human immunodeficiency virus (HIV) care in the developed world. Since the introduction of HAART the morbidity and mortality associated with HIV infection have decreased dramatically,1 but this benefit has been associated with the emergence of a diverse range of antiretroviral toxicities.

This publication has 0 references indexed in Scilit: